NCT07412613 2026-02-27
Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer
Akeso
Phase 3 Not yet recruiting
Akeso
Mirati Therapeutics Inc.
Nanjing Leads Biolabs Co.,Ltd
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Qilu Pharmaceutical Co., Ltd.
The First Affiliated Hospital of Zhengzhou University